Revelation Biosciences, Inc.
General ticker "REVB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $6.8M (TTM average)
Revelation Biosciences, Inc. does not follow the US Stock Market performance with the rate: -28.1%.
Estimated limits based on current volatility of 5.0%: low 0.93$, high 1.03$
Factors to consider:
- Total employees count: 9 as of 2024
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Economic downturns and volatility, Cybersecurity threats, Management challenges, Regulatory and compliance, Cost increases
- Current price 89.3% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [9.36$, 44.02$]
- 2025-12-31 to 2026-12-31 estimated range: [3.55$, 16.83$]
Financial Metrics affecting the REVB estimates:
- Negative: with PPE of -0.2 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -643.69 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Negative: Industry earnings per price (median), % of -16.34 <= 0
- Negative: Investing cash flow per share per price, % of -0.67 <= -0.66
- Negative: Shareholder equity ratio, % of 71.10 > 63.39
- Negative: -0.15 < Industry inventory ratio change (median), % of 0
Short-term REVB quotes
Long-term REVB plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $10.86MM | $8.66MM | $7.98MM |
| Operating Income | $-10.86MM | $-8.66MM | $-7.98MM |
| Non-Operating Income | $0.03MM | $8.54MM | $-7.06MM |
| R&D Expense | $5.38MM | $4.15MM | $3.55MM |
| Income(Loss) | $-10.83MM | $-0.12MM | $-15.04MM |
| Profit(Loss)* | $-10.83MM | $-0.12MM | $-15.04MM |
| Stockholders Equity | $1.05MM | $6.65MM | $4.71MM |
| Assets | $5.50MM | $12.21MM | $6.62MM |
| Operating Cash Flow | $-11.22MM | $-7.29MM | $-18.32MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.02MM |
| Investing Cash Flow | $0.00MM | $0.00MM | $-0.02MM |
| Financing Cash Flow | $15.20MM | $14.03MM | $12.85MM |
| Earnings Per Share** | $-9,643.41 | $-8.42 | $-87.68 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.